Isiguli Sokuqala Sifakwe Ukwelapha Okusha Kwe-Advanced Hepatocellular Carcinoma

A BAMBA Ukukhululwa Kwamahhala | eTurboNews | eTN
Ibhalwe ngu Linda Hohnholz

I-Kintor Pharmaceutical Limited namuhla imemezele umthamo wokuqala wesiguli e-United States wesilingo sayo somtholampilo sesigaba sesibili sesifunda (NCT05178043) se-ALK-1 antibody (GT90001) kanye ne-Nivolumab (Opdivo) yokwelashwa kwe-Advanced Hepatocellular Carcinoma (HCC) ngomhlaka-2 Meyi 2022.

NgokweGlobal Cancer Statistics 2020, umdlavuza wesibindi oyinhloko ungowesithupha umdlavuza ovame ukutholakala futhi uyimbangela yesithathu ehamba phambili yokufa komdlavuza emhlabeni wonke, cishe kube namacala amasha angama-906,000 nokufa kwabantu abangama-830,000[1]. I-HCC iwuhlobo oluvame kakhulu lomdlavuza wesibindi kubantu abadala, ebalelwa cishe ku-75% -85% wawo wonke umdlavuza wesibindi.[2] Sekukonke, ukwelashwa kanye nokubikezelwa komdlavuza wesibindi kubi kakhulu, futhi ukusinda kukonke komdlavuza wesibindi kudinga ukuthuthukiswa okwengeziwe ngezinketho zokwelashwa ezingcono.

Eminyakeni yamuva nje, izindlela zokwelapha ezintsha ziye zanda izinketho zeziguli ezinomdlavuza wesibindi othuthukile. Ngo-2020, inhlanganisela yokwelashwa kwe-Atezolizumab (TECENTRIQ®) ne-Bevacizumab (AVASTIN®) (“T+A”) yagunyazwa e-US ukuthi ithathe indawo ye-Sorafenib (NEXAVAR®) noma i-Lenvatinib (LENVIMA®) njengezinga lomugqa wokuqala ukunakekelwa (“i-SOC”) ye-HCC ethuthukisiwe, kulandela ukugunyazwa kwamanye amazwe nezifunda eziningi. Kube nezidingo ezinkulu ezingakafinyelelwa zokwelashwa komugqa wesibili ezigulini ezihlulekile ukwelashwa nge-T+A noma ezingayibekezeleli.

UDkt. Tong Youzhi, umsunguli, uSihlalo, kanye ne-CEO ye-Kintor Pharma, ubeke amazwana, “Sijabule ngokuqeda umthamo wokuqala wesiguli esigabeni sesi-II sokuhlolwa komtholampilo kwezifunda eziningi kwe-GT90001 kuhlanganiswe ne-Nivolumab yokwelashwa kwe-HCC ethuthukisiwe. Silindele ukuthi lesi sigaba sesi-II socwaningo lwe-MRCT luzobeka i-GT90001 kahle njengenhlanganisela yekhandidethi ene-I/O yokwelashwa komugqa wesibili kwe-HCC. Siphinde sikhethe amasu omtholampilo we-GT90001 kwamanye amathumba aqinile futhi sithemba ukuthi sizoletha izindlela ezintsha zokwelapha ezigulini ezinezidingo ezingafezeki.”

LOKHO ONGAKUTHATHE KULESI SIHLOKO:

  • U-Tong Youzhi, umsunguli, uSihlalo, kanye ne-CEO ye-Kintor Pharma, uphawule wathi, “Siyajabula ukuqeda umthamo wokuqala wesiguli esivivinyweni somtholampilo se-GT90001 sesigaba sesi-II esihlanganiswe ne-Nivolumab sokwelashwa kwe-HCC ethuthukisiwe.
  • I-Kintor Pharmaceutical Limited namuhla imemezele umthamo wokuqala wesiguli e-United States wesilingo sayo somtholampilo sesigaba sesibili sesifunda (NCT05178043) se-ALK-1 antibody (GT90001) kanye ne-Nivolumab (Opdivo) yokwelashwa kwe-Advanced Hepatocellular Carcinoma (HCC) ngomhlaka-2 Meyi 2022.
  • [2] Sekukonke, ukwelashwa kanye nokubikezelwa komdlavuza wesibindi kumpofu uma kuqhathaniswa, futhi ukuphila komdlavuza wesibindi sekukonke kudinga ukuthuthukiswa okwengeziwe ngezinketho zokwelashwa ezingcono.

<

Mayelana umbhali

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...